CN116963727A - 用于治疗眼部病症的药剂 - Google Patents

用于治疗眼部病症的药剂 Download PDF

Info

Publication number
CN116963727A
CN116963727A CN202180090238.6A CN202180090238A CN116963727A CN 116963727 A CN116963727 A CN 116963727A CN 202180090238 A CN202180090238 A CN 202180090238A CN 116963727 A CN116963727 A CN 116963727A
Authority
CN
China
Prior art keywords
group
alkyl
hydrogen
cycloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090238.6A
Other languages
English (en)
Chinese (zh)
Inventor
桑托什·C·辛哈
斯里达尔·戈文达·普拉萨德
马歇尔·C·彼得曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxair Pharmaceutical Co
Original Assignee
Praxair Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxair Pharmaceutical Co filed Critical Praxair Pharmaceutical Co
Priority claimed from PCT/US2021/072405 external-priority patent/WO2022104383A1/en
Publication of CN116963727A publication Critical patent/CN116963727A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180090238.6A 2020-11-13 2021-11-15 用于治疗眼部病症的药剂 Pending CN116963727A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63/113,691 2020-11-13
US202163215818P 2021-06-28 2021-06-28
US63/215,818 2021-06-28
PCT/US2021/072405 WO2022104383A1 (en) 2020-11-13 2021-11-15 Pharmacological agents for treating conditions of the eye

Publications (1)

Publication Number Publication Date
CN116963727A true CN116963727A (zh) 2023-10-27

Family

ID=84692077

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180090238.6A Pending CN116963727A (zh) 2020-11-13 2021-11-15 用于治疗眼部病症的药剂
CN202280058201.XA Pending CN117915900A (zh) 2021-06-28 2022-06-28 用于预防和治疗白内障和老花眼疾病的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280058201.XA Pending CN117915900A (zh) 2021-06-28 2022-06-28 用于预防和治疗白内障和老花眼疾病的药物

Country Status (7)

Country Link
US (1) US20240327439A1 (https=)
EP (1) EP4362923A4 (https=)
JP (1) JP2024524433A (https=)
CN (2) CN116963727A (https=)
CA (1) CA3225704A1 (https=)
MX (1) MX2024000116A (https=)
WO (1) WO2023278464A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
EP4243798A4 (en) * 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002461A1 (en) * 2002-05-17 2004-01-01 Matier William L. Amelioration of the development of cataracts and other ophthalmic diseases
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
US20190183842A1 (en) * 2016-08-24 2019-06-20 National Institute Of Biological Sciences, Beijing Entacapone-related Compounds to Treat Macular Degeneration
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID19540A (id) * 1997-01-22 1998-07-23 Hoffmann La Roche Metode pembuatan turunan-turunan benzofenon
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
KR20230021002A (ko) * 2020-06-09 2023-02-13 에이에스엠엘 홀딩 엔.브이. 내장 동축 조명부를 갖는 리소그래피 사전-정렬 이미징 센서
EP4243798A4 (en) * 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002461A1 (en) * 2002-05-17 2004-01-01 Matier William L. Amelioration of the development of cataracts and other ophthalmic diseases
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
US20190183842A1 (en) * 2016-08-24 2019-06-20 National Institute Of Biological Sciences, Beijing Entacapone-related Compounds to Treat Macular Degeneration
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"2377757-97-4，2377757-96-3，923287-50-7，747401-28-1", STN, 24 October 2019 (2019-10-24), pages 1 - 6 *
SNEHA SINGH: "Ocular Manifestations of Emerging Flaviviruses and the Blood-Retinal Barrier", VIRUSES, vol. 10, no. 10, 28 September 2018 (2018-09-28), pages 1 *
喻京生: "白内障", 31 January 2004, 山西科学技术出版社 *
毛俊峰: "左旋多巴对豚鼠形觉剥夺性近视形成的影响", 眼科研究, vol. 27, no. 4, 3 July 2009 (2009-07-03) *

Also Published As

Publication number Publication date
MX2024000116A (es) 2024-06-19
WO2023278464A1 (en) 2023-01-05
US20240327439A1 (en) 2024-10-03
CA3225704A1 (en) 2023-01-05
JP2024524433A (ja) 2024-07-05
EP4362923A4 (en) 2025-03-19
EP4362923A1 (en) 2024-05-08
CN117915900A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
US20230293527A1 (en) Treatment of inflammatory disorders
AU2019200623B2 (en) Compositions and methods for the treatment of presbyopia
US11872236B2 (en) Pharmacological agents for treating ocular diseases
US20240000812A1 (en) Pharmacological agents for treating conditions of the eye
AU2016280615A1 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
CN108601768A (zh) 用于治疗老花眼的组合物
TWI907473B (zh) 治療近視、預防近視及/或抑制近視進展之藥劑
CN116963727A (zh) 用于治疗眼部病症的药剂
US20220265783A1 (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
JP6499290B2 (ja) メラニンならびにメラニン類似体、前駆体、および誘導体による眼疾患、眼障害および眼症状の治療および予防のための方法
HK40103320A (zh) 用於治疗眼部病症的药剂
WO2022123837A1 (ja) 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法
JP7340237B2 (ja) 色素性乾皮症及び色素性乾皮症に起因する症状の予防／改善剤
e Silva et al. Suppression and regression of choroidal neovascularization by polyamine analogues
WO2023278604A1 (en) Pharmacological agents for treating ophthalmic diseases
CN114949229A (zh) 一种含有非甾体抗炎药的眼用药物组合物及其制备方法和用途
US20250144055A1 (en) Method and composition for reducing myopia progression
CN121337796B (zh) Compound-8在制备缓解或治疗蓝光损伤诱导的视网膜变性的产品中的应用
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
TW201318628A (zh) 含有黃素腺嘌呤二核苷酸或其塩為有效成分之角膜上皮細胞死亡抑制劑
He et al. TFE3-mediated neuroprotection: Clearance of aggregated a-synuclein and accumulated mitochondria in the AAV-a-synuclein model of Parkinson’s disease
Mowatt et al. Strategies for neuroprotection in glaucoma
WO2025067471A1 (zh) 一种α-肾上腺素受体激动剂眼用组合物及其用途
HK40050888A (en) Pharmacological agents for treating ocular diseases
WO2002024250A1 (en) Use of inos inhibitors for treating or preventing myopia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103320

Country of ref document: HK